Literature DB >> 33407700

Maintenance therapy in acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation.

Li Xuan1, Qifa Liu2.   

Abstract

Relapse remains the main cause of treatment failure in acute myeloid leukemia (AML) undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT). Emerging evidence has demonstrated that AML patients might benefit from maintenance therapy post-transplantation, especially for high-risk AML patients. In this mini-review, we will summarize targeted drugs, such as hypomethylating agents, FLT3 inhibitors and isocitrate dehydrogenase inhibitors, as maintenance therapy post-transplantation in AML patients undergoing allo-HSCT.

Entities:  

Keywords:  Acute myeloid leukemia; Allogeneic hematopoietic stem cell transplantation; Maintenance therapy; Targeted drugs

Year:  2021        PMID： 33407700      PMCID： PMC7786934          DOI： 10.1186/s13045-020-01017-7

Source DB:  PubMed          Journal:  J Hematol Oncol        ISSN： 1756-8722            Impact factor:   17.388


  54 in total

Review 1.  Hypomethylating agents for treatment and prevention of relapse after allogeneic blood stem cell transplantation.

Authors:  Thomas Schroeder; Christina Rautenberg; Rainer Haas; Ulrich Germing; Guido Kobbe
Journal:  Int J Hematol       Date:  2017-11-15       Impact factor: 2.490

2.  Efficacy and Feasibility of Sorafenib as a Maintenance Agent After Allogeneic Hematopoietic Stem Cell Transplantation for Fms-like Tyrosine Kinase 3 Mutated Acute Myeloid Leukemia: An Update.

Authors:  Giorgia Battipaglia; Radwan Massoud; Syed Osman Ahmed; Ollivier Legrand; Jean El Cheikh; Riad Youniss; Mahmoud Aljurf; Mohamad Mohty; Ali Bazarbachi
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2019-04-18

3.  A randomized comparison of daunorubicin 90 mg/m2 vs 60 mg/m2 in AML induction: results from the UK NCRI AML17 trial in 1206 patients.

Authors:  Alan K Burnett; Nigel H Russell; Robert K Hills; Jonathan Kell; Jamie Cavenagh; Lars Kjeldsen; Mary-Frances McMullin; Paul Cahalin; Mike Dennis; Lone Friis; Ian F Thomas; Don Milligan; Richard E Clark
Journal:  Blood       Date:  2015-04-01       Impact factor: 22.113

4.  AG-221, a First-in-Class Therapy Targeting Acute Myeloid Leukemia Harboring Oncogenic IDH2 Mutations.

Authors:  Katharine Yen; Jeremy Travins; Fang Wang; Muriel D David; Erin Artin; Kimberly Straley; Anil Padyana; Stefan Gross; Byron DeLaBarre; Erica Tobin; Yue Chen; Raj Nagaraja; Sung Choe; Lei Jin; Zenon Konteatis; Giovanni Cianchetta; Jeffrey O Saunders; Francesco G Salituro; Cyril Quivoron; Paule Opolon; Olivia Bawa; Véronique Saada; Angelo Paci; Sophie Broutin; Olivier A Bernard; Stéphane de Botton; Benoît S Marteyn; Monika Pilichowska; YingXia Xu; Cheng Fang; Fan Jiang; Wentao Wei; Shengfang Jin; Lee Silverman; Wei Liu; Hua Yang; Lenny Dang; Marion Dorsch; Virginie Penard-Lacronique; Scott A Biller; Shin-San Michael Su
Journal:  Cancer Discov       Date:  2017-02-13       Impact factor: 38.272

5.  The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate.

Authors:  Patrick S Ward; Jay Patel; David R Wise; Omar Abdel-Wahab; Bryson D Bennett; Hilary A Coller; Justin R Cross; Valeria R Fantin; Cyrus V Hedvat; Alexander E Perl; Joshua D Rabinowitz; Martin Carroll; Shinsan M Su; Kim A Sharp; Ross L Levine; Craig B Thompson
Journal:  Cancer Cell       Date:  2010-02-18       Impact factor: 38.585

6.  Chemotherapy and Venetoclax in Elderly Acute Myeloid Leukemia Trial (CAVEAT): A Phase Ib Dose-Escalation Study of Venetoclax Combined With Modified Intensive Chemotherapy.

Authors:  Chong Chyn Chua; Andrew W Roberts; John Reynolds; Chun Yew Fong; Stephen B Ting; Jessica M Salmon; Sarah MacRaild; Adam Ivey; Ing Soo Tiong; Shaun Fleming; Fiona C Brown; Sun Loo; Ian J Majewski; Stefan K Bohlander; Andrew H Wei
Journal:  J Clin Oncol       Date:  2020-07-20       Impact factor: 50.717

Review 7.  Emerging therapies for acute myeloid leukemia.

Authors:  Caner Saygin; Hetty E Carraway
Journal:  J Hematol Oncol       Date:  2017-04-18       Impact factor: 17.388

8.  Phase I/II study of the deacetylase inhibitor panobinostat after allogeneic stem cell transplantation in patients with high-risk MDS or AML (PANOBEST trial).

Authors:  G Bug; A Burchert; E-M Wagner; N Kröger; T Berg; S Güller; S K Metzelder; A Wolf; S Hünecke; P Bader; J Schetelig; H Serve; O G Ottmann
Journal:  Leukemia       Date:  2017-07-28       Impact factor: 11.528

9.  Leukemia relapse following unmanipulated haploidentical transplantation: a risk factor analysis on behalf of the ALWP of the EBMT.

Authors:  Simona Piemontese; Ariane Boumendil; Myriam Labopin; Christoph Schmid; Fabio Ciceri; William Arcese; Yener Koc; Zafar Gulbas; Johanna Tischer; Benedetto Bruno; Depei Wu; Didier Blaise; Dietrich Beelen; Giuseppe Irrera; Annalisa Ruggeri; Mohamed Houhou; Mohamad Mohty; Arnon Nagler
Journal:  J Hematol Oncol       Date:  2019-07-04       Impact factor: 17.388

10.  CC-486 Maintenance after Stem Cell Transplantation in Patients with Acute Myeloid Leukemia or Myelodysplastic Syndromes.

Authors:  Marcos de Lima; Betul Oran; Richard E Champlin; Esperanza B Papadopoulos; Sergio A Giralt; Bart L Scott; Basem M William; Joel Hetzer; Eric Laille; Becky Hubbell; Barry S Skikne; Charles Craddock
Journal:  Biol Blood Marrow Transplant       Date:  2018-06-20       Impact factor: 5.742
View more
  9 in total

1.  Effect of pediatric- versus adult-type chemotherapy regimens on outcomes of allogeneic hematopoietic stem cell transplants for adult T-cell acute lymphoblastic leukemia in first complete remission.

Authors:  Han-Zhou Qi; Jun Xu; Qian-Qian Yang; Ren Lin; Zhi-Xiang Wang; Ke Zhao; Qiang Wang; Xuan Zhou; Zhi-Ping Fan; Fen Huang; Na Xu; Li Xuan; Hua Jin; Jing Sun; Robert Peter Gale; Hong-Sheng Zhou; Qi-Fa Liu
Journal:  Bone Marrow Transplant       Date:  2022-08-30       Impact factor: 5.174

2.  Circular RNA circCRKL inhibits the proliferation of acute myeloid leukemia cells via the miR-196a-5p/miR-196b-5p/p27 axis.

Authors:  Wen Liu; Fanjun Cheng
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

3.  Maintenance With Hypomethylating Agents After Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia and Myelodysplastic Syndrome: A Systematic Review and Meta-Analysis.

Authors:  Smith Kungwankiattichai; Ben Ponvilawan; Claudie Roy; Pattaraporn Tunsing; Florian Kuchenbauer; Weerapat Owattanapanich
Journal:  Front Med (Lausanne)       Date:  2022-02-15

4.  Outcomes of allogeneic haematopoietic stem cell transplantation for paediatric patients with MLL-rearranged acute myeloid leukaemia.

Authors:  Lu Bai; Yong-Zhan Zhang; Chen-Hua Yan; Yu Wang; Lan-Ping Xu; Xiao-Hui Zhang; Le-Ping Zhang; Xiao-Jun Huang; Yi-Fei Cheng
Journal:  BMC Cancer       Date:  2022-08-16       Impact factor: 4.638

5.  Effect of sorafenib maintenance on Epstein-Barr virus and cytomegalovirus infections in patients with FLT3-ITD AML undergoing allogeneic hematopoietic stem cell transplantation: a secondary analysis of a randomized clinical trial.

Authors:  Xin Xu; Zhiping Fan; Yu Wang; Fen Huang; Yajing Xu; Jing Sun; Na Xu; Lan Deng; Xudong Li; Xinquan Liang; Xiaodan Luo; Pengcheng Shi; Hui Liu; Yan Chen; Sanfang Tu; Xiaojun Huang; Qifa Liu; Li Xuan
Journal:  BMC Med       Date:  2022-09-02       Impact factor: 11.150

Review 6.  Generalist in allogeneic hematopoietic stem cell transplantation for MDS or AML: Epigenetic therapy.

Authors:  Guancui Yang; Xiang Wang; Shiqin Huang; Ruihao Huang; Jin Wei; Xiaoqi Wang; Xi Zhang
Journal:  Front Immunol       Date:  2022-10-04       Impact factor: 8.786

Review 7.  Therapeutic Use of Valproic Acid and All-Trans Retinoic Acid in Acute Myeloid Leukemia-Literature Review and Discussion of Possible Use in Relapse after Allogeneic Stem Cell Transplantation.

Authors:  Øystein Bruserud; Galina Tsykunova; Maria Hernandez-Valladares; Hakon Reikvam; Tor Henrik Anderson Tvedt
Journal:  Pharmaceuticals (Basel)       Date:  2021-05-02

8.  Novel CD123 polyaptamer hydrogel edited by Cas9/sgRNA for AML-targeted therapy.

Authors:  Haibin Wu; Liyu Zhang; Zeen Zhu; Chenxi Ding; Shengquan Chen; Ruiping Liu; Huafeng Fan; Yang Chen; Hui Li
Journal:  Drug Deliv       Date:  2021-12       Impact factor: 6.419

Review 9.  Fate of hematopoietic stem cells determined by Notch1 signaling (Review).

Authors:  Yidong Ge; Jie Wang; Hui Zhang; Jinyun Li; Meng Ye; Xiaofeng Jin
Journal:  Exp Ther Med       Date:  2021-12-27       Impact factor: 2.447
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.